Biological evalution of thiazole derivatives bearing dithiocarbamate moiety as potential cholinesterase inhibitors

2 chloro N [4 (2 methyl 4 thiazolyl)phenyl]acetamide; 2 [[4 (2 methyl 4 thiazolyl) phenyl] amino] 2 oxoethyl 4 (2 hydroxyethyl) piperazine 1 carbodithioate; 2 [[4 (2 methyl 4 thiazolyl) phenyl] amino] 2 oxoethyl 4 substitutedpiperazine 1 carbodithioate; 2 [[4 (2 methyl 4 thiazolyl)phenyl]amino] 2 oxoethyl 4 (4 fluorophenyl)piperazine 1 carbodithioate; 2 [[4 (2 methyl 4 thiazolyl)phenyl]amino] 2 oxoethyl 4 (4 methoxyphenyl)piperazine 1 carbodithioate; 2 [[4 (2 methyl 4 thiazolyl)phenyl]amino] 2 oxoethyl 4 (4 methylbenzyl)piperazine 1 carbodithioate; 2 [[4 (2 methyl 4 thiazolyl)phenyl]amino] 2 oxoethyl 4 (4 nitrophenyl)piperazine 1 carbodithioate; 2 [[4 (2 methyl 4 thiazolyl)phenyl]amino] 2 oxoethyl 4 cyclo hexylpiperazine 1 carbodithioate; 2 [[4 (2 methyl 4 thiazolyl)phenyl]amino] 2 oxoethyl 4 phenyl piperazine 1 carbodithioate; 2 [[4 (2 Methyl 4 thiazolyl)phenyl]amino] 2 oxoethyl 4 [2 (N N dimethylamino)ethyl]piperazine 1 carbodithioate; 2 [[4 (2 methyl 4 thiazolyl)phenyl]amino] 2 oxoethyl 4 [3 (N N dimethylamino)propyl]piperazine 1 carbodithioate; acetylcholinesterase; cholinesterase inhibitor; dithiocarbamic acid; thiazole derivative; unclassified drug; Article; carbon nuclear magnetic resonance; chemical parameters; cholinesterase inhibition; drug screening; drug synthesis; Ellmans spectophotometry; enzymatic assay; enzyme inhibition; IC50; infrared spectrometry; mass spectrometry; proton nuclear magnetic resonance; spectrophotometry